MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Allogene Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.25 1.63

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.24

Max

1.31

Pagrindiniai rodikliai

By Trading Economics

Pajamos

206K

-60M

Pelno marža

272,450

Darbuotojai

226

EBITDA

-302K

-56M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+593.6% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

26M

282M

Ankstesnė atidarymo kaina

-0.38

Ankstesnė uždarymo kaina

1.25

Naujienos nuotaikos

By Acuity

50%

50%

154 / 376 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Allogene Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-18 21:01; UTC

Uždarbis

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

2025-07-18 20:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-07-18 20:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-07-18 20:50; UTC

Rinkos pokalbiai
Uždarbis

Basic Materials Roundup: Market Talk

2025-07-18 20:46; UTC

Uždarbis

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

2025-07-18 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025-07-18 20:36; UTC

Uždarbis

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

2025-07-18 20:16; UTC

Įsigijimai, susijungimai, perėmimai

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

2025-07-18 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-18 20:02; UTC

Rinkos pokalbiai

Gold Higher to Close Out Week -- Market Talk

2025-07-18 19:14; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

2025-07-18 19:06; UTC

Rinkos pokalbiai

Oil Futures Snap Two-Week Winning Streak -- Market Talk

2025-07-18 18:24; UTC

Uždarbis

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

2025-07-18 18:19; UTC

Uždarbis

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

2025-07-18 18:11; UTC

Įsigijimai, susijungimai, perėmimai

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

2025-07-18 18:11; UTC

Uždarbis

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

2025-07-18 17:35; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

2025-07-18 16:29; UTC

Rinkos pokalbiai

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

2025-07-18 16:28; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025-07-18 16:22; UTC

Uždarbis

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Energy & Utilities Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Basic Materials Roundup: Market Talk

2025-07-18 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-18 16:04; UTC

Uždarbis

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

2025-07-18 15:58; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-18 15:58; UTC

Rinkos pokalbiai

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

2025-07-18 15:47; UTC

Rinkos pokalbiai
Uždarbis

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Akcijų palyginimas

Kainos pokytis

Allogene Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

593.6% į viršų

12 mėnesių prognozė

Vidutinis 8.67 USD  593.6%

Aukščiausias 14 USD

Žemiausias 4 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Allogene Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

11

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.18 / 1.69Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

154 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.